Instil Bio, Inc. Overview
Pro stress-test →Instil Bio is a clinical-stage biopharmaceutical company developing a pipeline of cell therapies, specifically autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Strategic Profile
Pro stress-test →The company focuses on engineered tumor infiltrating lymphocyte (TIL) cell therapies using its proprietary Co-Stimulatory Antigen Receptor (CoStAR) platform. Its lead candidate AXN-2510/IMM2510 is in Phase 1b/2 trials for advanced/metastatic non-small cell lung cancer, with additional Phase 1 studies in China exploring multiple solid tumor types.
Competitive Landscape
Pro stress-test →Instil Bio competes in the CAR-T/TIL cell therapy space dominated by larger players like Novartis (Kymriah), Gilead (Yescarta), and emerging competitors like Iovance Biotherapeutics and Legend Biotech. TIL therapies represent a growing but smaller segment compared to CAR-T. Competitive advantages lie in CoStAR platform differentiation and FRA-targeting focus, though limited resources constrain development speed versus well-funded competitors.
Industry Context
Instil Bio, Inc. operates in Biopharmaceutical - Immunotherapy/Cell Therapy.
Key facts
Founded: 2018 · Headquarters: Dallas, United States · Employees: 14 · Market cap: $44.8M